Lilian Gien, MD, Reviews Pembrolizumab Plus Epacadostat in Recurrent Clear Cell Carcinoma of the Ovary


At 2022 IGCS, Lilian Gien, MD, spoke about a phase 2 trial which analyzed pembrolizumab plus epacadostat in patients with recurrent clear cell carcinoma of the ovary.

During the 2022 Annual Global Meeting of the International Gynecologic Cancer Society, CancerNetwork® spoke with Lilian Gien, MD, a gynecologic oncologist from Sunnybrook Health Sciences Centre in Toronto, Canada, about results from a phase 2 trial (NCT03602586) investigating pembrolizumab (Keytruda) plus the IDO1 inhibitor epacadostat.

The objective response rate was 21% (95% CI, 0.05-0.51) and patients had a median duration of response of 6.9 months. Out of a cohort of 14 patients, 3 had a partial response and 4 had stable disease for a disease control rate of 50%. Additionally, the median progression-free survival was 4.8 months (95% CI, 1.9-9.6) and the median overall survival was 18.9 months (95% CI, 1.9-not reached).

Although the investigators ultimately determined that the results were inconclusive for determining a benefit of the addition of epacadostat to pembrolizumab in this setting, the results were thought provoking and add to what is known about immunotherapy use.


We know that recurrent clear cell cancers of the ovary are an area of unmet need. We do know that in any phase 2 studies that have been done on all epithelial ovarian cancers that include clear cell, responses to immunotherapy monotherapy is around 15%. Among those studies, we saw that clear cell carcinomas, in particular, seem to have a more pronounced and durable response than other types of ovarian cancer. We thought we could build on that by seeing if we can improve the 15% overall response rate with a combination therapy, particularly for ovarian cancers that are clear cell and have a poor response to chemotherapy otherwise.

This was a single-arm phase 2 study of recurrent or metastatic clear cell cancers of the ovary. We gave 2 agents, one was pembrolizumab at 200 mg intravenously every 3 weeks, as well as an IDO1 inhibitor called epacadastat, which was given at 100 mg orally twice a day. The combination of those 2 was given together until progression or toxicity, and the overall response rate was the primary end point. There was approximately a 21% overall response rate. This was in a small cohort of patients. The plan for the sample size was to recruit enough patients for the first stage, and if there was adequate response then open it up to the second stage for a total of 23 patients. We recruited the first 14 patients in the first stage quickly and that’s what we did the analysis on. Because of a number of logistical issues, we were unable to complete the study up to the full 23 patients. In the small cohort that we had with 14 patients, the response rate was 21%.

There was mostly grade 1 and 2 adverse effects, things like nausea, vomiting, and some electrolyte abnormalities. The grade 3 adverse effects were things like bowel obstruction, and there were some nutritional issues as well. Overall, the vast majority were grade 1 and 2.


Gien LT, Enseroo DM, Block MS, et al. Phase II trial of pembrolizumab and epacadostat in recurrent clear cell carcinoma of the ovary: an NRG Oncology Study (NRG-GY016). Presented at: 2022 Annual Global Meeting of the International Gynecologic Cancer Society; New York, NY; September 29-October 1, 2022. Abstract O014.

Related Videos
Brian Slomovitz, MD, MS, FACOG discusses the use of new antibody drug conjugates for treating patients with various gynecologic cancers.
Developing novel regimens may continue to improve survival outcomes of patients with advanced cervical cancer following the FDA approval of pembrolizumab and chemoradiation, says Jyoti S. Mayadev, MD.
Treatment with pembrolizumab plus chemoradiation appears to be well tolerated with no detriment to quality of life among those with advanced cervical cancer.
Jyoti S. Mayadev, MD, says that pembrolizumab in combination with chemoradiation will be seamlessly incorporated into her institution’s treatment of those with FIGO 2014 stage III to IVA cervical cancer following the regimen’s FDA approval.
Treatment with tisotumab vedotin may be a standard of care in second- or third-line recurrent or metastatic cervical cancer, says Brian Slomovitz, MD, MS, FACOG.
Domenica Lorusso, MD, PhD, says that paying attention to the quality of chemoradiotherapy is imperative to feeling confident about the potential addition of pembrolizumab for locally advanced cervical cancer.
Future analyses will look at durvalumab/olaparib for endometrial cancer populations with TP53 and POLE alterations, as well as those with estrogen receptor and progesterone receptor positivity.
Patients with mismatch repair proficient, newly diagnosed, advanced or recurrent endometrial cancer may have enhanced benefit with the addition of olaparib to durvalumab.
Guidelines from the Society of Gynecologic Oncology may help with managing the ongoing chemotherapy shortage in the treatment of patients with gynecologic cancers, according to Brian Slomovitz, MD, MS, FACOG.
Brian Slomovitz, MD, MS, FACOG, notes that sometimes there is a need to substitute cisplatin for carboplatin, and vice versa, to best manage gynecologic cancers during the chemotherapy shortage.
Related Content